MCID: HML018
MIFTS: 22

Homologous Wasting Disease

Categories: Rare diseases

Aliases & Classifications for Homologous Wasting Disease

MalaCards integrated aliases for Homologous Wasting Disease:

Name: Homologous Wasting Disease 52
Graft-Vs-Host Disease 71

Classifications:



External Ids:

UMLS 71 C0018133

Summaries for Homologous Wasting Disease

MalaCards based summary : Homologous Wasting Disease, is also known as graft-vs-host disease. The drugs Posaconazole and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow.

Related Diseases for Homologous Wasting Disease

Symptoms & Phenotypes for Homologous Wasting Disease

Drugs & Therapeutics for Homologous Wasting Disease

Drugs for Homologous Wasting Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 334)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
2
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
3
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
4
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
11
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
12
Simethicone Approved Phase 4 8050-81-5
13
Povidone Approved Phase 4 9003-39-8
14
Semustine Experimental, Investigational Phase 4 13909-09-6
15
Treosulfan Investigational Phase 4 299-75-2 9296
16 Antiprotozoal Agents Phase 4
17 Antiparasitic Agents Phase 4
18 Histone Deacetylase Inhibitors Phase 4
19 Thymoglobulin Phase 4
20 Adjuvants, Immunologic Phase 4
21 Cytochrome P-450 Enzyme Inhibitors Phase 4
22 Lubricant Eye Drops Phase 4
23 Protective Agents Phase 4
24
Hydroxyitraconazole Phase 4
25 Cytochrome P-450 CYP3A Inhibitors Phase 4
26 Antacids Phase 4
27 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
28 Anti-Ulcer Agents Phase 4
29 Viscosupplements Phase 4
30 Plasma Substitutes Phase 4
31 Blood Substitutes Phase 4
32
Budesonide Approved Phase 3 51333-22-3 63006 5281004
33
Carmustine Approved, Investigational Phase 2, Phase 3 154-93-8 2578
34
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
36
Acyclovir Approved Phase 3 59277-89-3 2022
37
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
38
Hydroxychloroquine Approved Phase 3 118-42-3 3652
39
Idarubicin Approved Phase 3 58957-92-9 42890
40
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
41
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
42
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
43
Pegaspargase Approved, Investigational Phase 3 130167-69-0
44
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
45
Sodium citrate Approved, Investigational Phase 3 68-04-2
46
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
47
Hydroxyurea Approved Phase 3 127-07-1 3657
48
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
49
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
50
Daunorubicin Approved Phase 3 20830-81-3 30323

Interventional clinical trials:

(show top 50) (show all 837)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
3 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
4 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
5 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
6 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
7 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
8 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
9 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
10 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
11 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
12 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
13 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
14 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation
15 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
16 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
17 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
18 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
19 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
20 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
21 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
22 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
23 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
24 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
25 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation Unknown status NCT00450450 Phase 3
26 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
27 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
28 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
29 A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
30 Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD Completed NCT00887263 Phase 3 Budesonide;Placebo
31 An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients Completed NCT00037531 Phase 3 Sirolimus (RAPAMUNE)
32 Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease Completed NCT00034645 Phase 3 Posaconazole oral suspension
33 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
34 Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide
35 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
36 A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms Completed NCT00043147 Phase 3 beclomethasone dipropionate;methylprednisolone;prednisone
37 Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
38 A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients. Completed NCT00167947 Phase 3 Cyclosporine;Steroids;Rapamune (Sirolimus)
39 Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation Completed NCT00001561 Phase 3 Myeloma Immunoglobulin Idiotype Vaccine-KLH;GM-CSF
40 A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors Completed NCT00195273 Phase 3 sirolimus;cyclosporine;mycophenolate mofetil;corticosteroids;daclizumab
41 A Randomized, Placebo-Controlled, Multi-Center Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal Graft Vs. Host Disease Completed NCT00233896 Phase 3 Oral beclomethasone dipropionate (drug)
42 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
43 GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S Completed NCT00655343 Phase 3 ATG-Fresenius S
44 Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02652130 Phase 3
45 A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631 Completed NCT01149096 Phase 3
46 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
47 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
48 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
49 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
50 A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT00366145 Phase 3 Standard of Care for GVHD

Search NIH Clinical Center for Homologous Wasting Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Daclizumab
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Tacrolimus
Thalidomide

Genetic Tests for Homologous Wasting Disease

Anatomical Context for Homologous Wasting Disease

MalaCards organs/tissues related to Homologous Wasting Disease:

40
T Cells, Bone, Bone Marrow, Myeloid, Skin, Eye, Liver

Publications for Homologous Wasting Disease

Articles related to Homologous Wasting Disease:

(show top 50) (show all 2192)
# Title Authors PMID Year
1
Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics. 61
32537004 2020
2
Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. 61
32526079 2020
3
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. 61
32496525 2020
4
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. 61
32499241 2020
5
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. 61
32382774 2020
6
Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low dose total body irradiation and rabbit antithymocyte globulin. 61
32573834 2020
7
Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. 61
32573983 2020
8
Incidence, risk factors, and clinical outcomes associated with Epstein-Barr virus-DNAemia and Epstein-Barr virus-associated disease in patients after haploidentical allogeneic stem cell transplantation: A single-center study. 61
32170765 2020
9
A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplant patients. 61
32505809 2020
10
The QuantiFERON Monitor® assay is predictive of infection post allogeneic hematopoietic cell transplantation. 61
32034973 2020
11
Are apoptosis-determining techniques useful to establish an early diagnosis of acute graft-vs-host disease in pediatric patients under treatment with multiple drugs? 61
32031289 2020
12
Infectious complications in pediatric allogeneic hematopoietic stem cell transplantation recipients - A retrospective clinical and epidemiological cohort study. 61
32538520 2020
13
Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. 61
32022292 2020
14
Second Allogeneic Hematopoietic Stem Cell Transplantation After Donor Replacement in Children With Severe Aplastic Anemia. 61
32444128 2020
15
Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Case Report. 61
32444124 2020
16
Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. 61
32458063 2020
17
Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease. 61
32064745 2020
18
Extracorporeal photopheresis for graft-vs-host disease: A literature review and treatment guidelines proposed by the Nordic ECP Quality Group. 61
31908057 2020
19
Soluble Interleukin-2 Receptor Index Predicts Outcomes After Cord Blood Transplantation. 61
32389487 2020
20
Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation. 61
32386102 2020
21
Macrophage regulation of graft-vs-host disease. 61
32518770 2020
22
Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. 61
32202691 2020
23
Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model. 61
32385957 2020
24
Killer-cell immunoglobulin-like receptor assessment algorithms in haemopoietic progenitor cell transplantation: current perspectives and future opportunities. 61
31999071 2020
25
Graft-versus-host disease: a case report of a rare but reversible cause of constrictive pericarditis. 61
32352060 2020
26
CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). 61
32303111 2020
27
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. 61
32286544 2020
28
Toxoplasma-induced hemophagocytic lymphohistiocytosis after haploidentical allogeneic stem cell transplantation. 61
31895492 2020
29
Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study. 61
32311156 2020
30
Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. 61
32301566 2020
31
Role of antithymocyte globulin in patients with hematologic diseases undergoing umbilical cord blood transplantation: A systematic review and meta-analysis. 61
32277839 2020
32
BK polyomavirus nephropathy with systemic viral spread: Whole genome sequencing data from a fatal case of BKPyV infection. 61
32090422 2020
33
N-glycosylation controls inflammatory licensing-triggered PD-L1 upregulation in human mesenchymal stromal cells. 61
32346937 2020
34
Intracellular cathepsin C levels determine sensitivity of cells to leucyl-leucine methyl ester-triggered apoptosis. 61
32319717 2020
35
Diagnoses of hospitalized patients with skin abnormalities prompting biopsy by consulting dermatologists: A 3-year review from a tertiary care center. 61
31845375 2020
36
Machine Learning Algorithms to Differentiate Among Pulmonary Complications After Hematopoietic Cell Transplant. 61
32343962 2020
37
Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. 61
31769937 2020
38
Observer agreement for the diagnosis of intestinal acute graft-vs.-host disease based on the presence of villous atrophy in the terminal ileum. 61
32256795 2020
39
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). 61
31558789 2020
40
Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. 61
32203268 2020
41
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report. 61
32035679 2020
42
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. 61
31804748 2020
43
Yoga for Cancer-Related Fatigue in Survivors of Hematopoietic Cell Transplantation: A Feasibility Study. 61
31765760 2020
44
Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model. 61
32104226 2020
45
Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children. 61
31951682 2020
46
Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. 61
32258077 2020
47
The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. 61
32157246 2020
48
Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia. 61
32024992 2020
49
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. 61
31862477 2020
50
Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. 61
30892982 2020

Variations for Homologous Wasting Disease

Expression for Homologous Wasting Disease

Search GEO for disease gene expression data for Homologous Wasting Disease.

Pathways for Homologous Wasting Disease

GO Terms for Homologous Wasting Disease

Sources for Homologous Wasting Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....